Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML
Status:
Completed
Trial end date:
2019-10-15
Target enrollment:
Participant gender:
Summary
This protocol corresponds to a multicenter, open-label, non-randomized, phase I study
designed to determine the safety of the combination of selinexor with chemotherapy in young
patients with relapsed or refractory AML.
The clinical trial is divided into pre-treatment, treatment (induction and consolidation
cycles) and follow-up periods and consists of a phase I design in which es-calating doses of
selinexor will be given to 3 groups, each with 3-6 patients until achieving the maximum
tolerated dose (MTD).